REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Clinical trials for REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for High-Risk blood cancer: targeted therapy shows promise
Disease control Recruiting nowThis study tests a combination of two drugs, enasidenib and azacitidine, in people with a rare, high-risk blood cancer called IDH2-mutant myelodysplastic syndrome. The goal is to see if the treatment can control the disease and reduce side effects. About 63 participants will take…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug cocktail shows promise for tough blood cancers
Disease control Recruiting nowThis study tests a combination of four drugs (cladribine, idarubicin, cytarabine, and quizartinib) in people with acute myeloid leukemia or high-risk myelodysplastic syndrome that is either newly diagnosed or has returned/not responded to treatment. The goal is to see if this mix…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Experimental drug combo offers hope for Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial tests a chemotherapy drug called CPX-351 in people with high-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) that came back or didn't respond to standard treatment. The main goals are to find the safest dose and check for side…
Matched conditions: REFRACTORY HIGH RISK MYELODYSPLASTIC SYNDROME
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:41 UTC